Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism
Nissim Haim, Naomi Lanir, Ron Hoffman et al. · The American Journal of Medicine · 2001
Cited by 97 works. doi:10.1016/s0002-9343(00)00691-4
Authors
References
- Reporting results of cancer treatment
- Mutation in blood coagulation factor V associated with resistance to activated protein C
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
- Systemic Lupus Erythematosus
- Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]
- Venous thromboembolism and cancer
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives
- Laboratory Diagnosis of APC-Resistance: A Critical Evaluation of the Test and the Development of Diagnostic Criteria
- Pathophysiology of the Thrombophilic State in the Cancer Patient
- A Reduced Sensitivity for Activated Protein C in the Absence of Factor V Leiden Increases the Risk of Venous Thrombosis